The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature

被引：2

作者：

Botticelli, Andrea ^{[1
,2
]}

Fabbri, Agnese ^{[3
]}

Roberto, Michela ^{[2
,4
]}

Alesini, Daniele ^{[5
]}

Cirillo, Alessio ^{[1
,6
]}

D'Auria, Giuliana ^{[7
]}

Krasniqi, Eriseld ^{[8
]}

Marrucci, Eleonora ^{[3
]}

Muratore, Margherita ^{[9
]}

Pantano, Francesco ^{[10
]}

Pizzuti, Laura ^{[8
]}

Portarena, Ilaria ^{[11
]}

Rossi, Rosalina ^{[12
]}

Scagnoli, Simone ^{[1
,13
]}

Marchetti, Paolo ^{[2
]}

机构：

[1] Policlin Umberto 1, Med Oncol Unit B, Rome, Italy

[2] Sapienza Univ Rome, St Andrea Hosp, Dept Clin & Mol Med, Oncol Unit, Rome, Italy

[3] Belcolle Hosp, Med Oncol Unit, Viterbo, Italy

[4] Policlin Umberto 1, Med Oncol Unit, Rome, Italy

[5] Osped Santo Spirito Sassia, UOSD Ctr Oncol S Spirito & Nuovo Regina Margherit, Rome, Italy

[6] Sapienza Univ Rome, Dept Radiol Oncol & Anatomopathol Sci, Rome, Italy

[7] Sandro Pertini Hosp, Dept Med Oncol, Rome, Italy

[8] Ist Ricovero & Cura Carattere Sci IRCCS, Div Med Oncol 2, Rome, Italy

[9] Fdn Policlin Univ Agostino Gemelli, Div Gynecol Oncol, Dept Woman & Child Hlth & Publ Hlth, Ist Ricovero & Cura Carattere Sci IRCCS, Rome, Italy

[10] Univ Campus Biomed Rome, Dept Oncol, Rome, Italy

[11] Univ Hosp, Dept Internal Med, Med Oncol Unit, Tor Vergata Clin Ctr, Rome, Italy

[12] San Giovanni Addolorata Hosp, Med Oncol, Rome, Italy

[13] Sapienza Univ Rome, Dept Med & Surg Sci & Translat Med, Rome, Italy

来源：

FRONTIERS IN ONCOLOGY | 2022年 / 12卷

关键词：

CDK4; 6; inhibitor; oligometastatic; locally advanced breast cancer (LABC); ribociclib; case report; ENDOCRINE THERAPY; PLUS LETROZOLE; OPEN-LABEL; PALBOCICLIB; FULVESTRANT; CHEMOTHERAPY; MULTICENTER; ABEMACICLIB; SURVIVAL; WOMEN;

D O I：

10.3389/fonc.2022.797157

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The recent addition of cyclin-dependent kinase 4 (CDK4) and CDK6 inhibitors to endocrine therapy has remarkably improved the outcome of patients affected with hormone receptor positive (HR+), human epidermal grow factor receptor 2 negative (HER2 -) advanced breast cancer (ABC). Ribociclib showed to be effective across most subgroups, regardless of the number and the site of metastasis. Up to 10% of patients with ABC, reported an oligometastatic condition, recently defined as a slow-volume metastatic disease with limited number and size of metastatic lesions (up to 5 and not necessarily in the same organ), potentially amenable for local treatment, aimed at achieving a complete remission status. Despite the wide use of CDK4/6 inhibitors in HR+, HER2-, ABC treatment, data regarding both locally advanced, inoperable disease and oligometastatic conditions are still poor. We reported a review and case series of HR+, HER2-, ABC patients treated with ribociclib as first-line therapy, for a locally advanced and oligometastatic conditions, reporting an impressive response and good safety profile.

引用

页数：8

共 32 条

[1] Modulation of Rb phosphorylation and antiproliferative response to palbociclib: the preoperative-palbociclib (POP) randomized clinical trial [J].

Arnedos, M. ;

Bayar, M. A. ;

Cheaib, B. ;

Scott, V. ;

Bouakka, I. ;

Valent, A. ;

Adam, J. ;

Leroux-Koza, V. ;

Marty, V. ;

Rapinat, A. ;

Mazouni, C. ;

Sarfati, B. ;

Bieche, I. ;

Balleyguier, C. ;

Gentien, D. ;

Delaloge, S. ;

Lacroix-Triki, M. ;

Michiels, S. ;

Andre, F. .

ANNALS OF ONCOLOGY, 2018, 29 (08) :1755-1762

[2] Locoregional treatment versus no treatment of the primary tumour in metastatic breast cancer: an open-label randomised controlled trial [J].

Badwe, Rajendra ;

Hawaldar, Rohini ;

Nair, Nita ;

Kaushik, Rucha ;

Parmar, Vani ;

Siddique, Shabina ;

Budrukkar, Ashwini ;

Mittra, Indraneel ;

Gupta, Sudeep .

LANCET ONCOLOGY, 2015, 16 (13) :1380-1388

[3] 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) [J].

Cardoso, F. ;

Paluch-Shimon, S. ;

Senkus, E. ;

Curigliano, G. ;

Aapro, M. S. ;

Andre, F. ;

Barrios, C. H. ;

Bergh, J. ;

Bhattacharyya, G. S. ;

Biganzoli, L. ;

Boyle, F. ;

Cardoso, M-J ;

Carey, L. A. ;

Cortes, J. ;

El Saghir, N. S. ;

Elzayat, M. ;

Eniu, A. ;

Fallowfield, L. ;

Francis, P. A. ;

Gelmon, K. ;

Gligorov, J. ;

Haidinger, R. ;

Harbeck, N. ;

Hu, X. ;

Kaufman, B. ;

Kaur, R. ;

Kiely, B. E. ;

Kim, S-B ;

Lin, N. U. ;

Mertz, S. A. ;

Neciosup, S. ;

Offersen, B., V ;

Ohno, S. ;

Pagani, O. ;

Prat, A. ;

Penault-Llorca, F. ;

Rugo, H. S. ;

Sledge, G. W. ;

Thomssen, C. ;

Vorobiof, D. A. ;

Wiseman, T. ;

Xu, B. ;

Norton, L. ;

Costa, A. ;

Winer, E. P. .

ANNALS OF ONCOLOGY, 2020, 31 (12) :1623-1649

[4] Overall survival (OS) with palbociclib (PAL) plus fulvestrant (FUL) in women with hormone receptor-positive (HR plus ), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3. [J].

Cristofanilli, Massimo ;

Rugo, Hope S. ;

Im, Seock-Ah ;

Slamon, Dennis J. ;

Harbeck, Nadia ;

Bondarenko, Igor ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Iwata, Sherene Loi Hiroji ;

O'Leary, Ben ;

Bananis, Eustratios ;

Liu, Yuan ;

Huang, Xin ;

Kim, Sindy ;

Lechuga, Mariajose ;

Turner, Nicholas C. .

JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)

[5] Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial [J].

Cristofanilli, Massimo ;

Turner, Nicholas C. ;

Bondarenko, Igor ;

Ro, Jungsil ;

Im, Seock-Ah ;

Masuda, Norikazu ;

Colleoni, Marco ;

DeMichele, Angela ;

Loi, Sherene ;

Verma, Sunil ;

Iwata, Hiroji ;

Harbeck, Nadia ;

Zhang, Ke ;

Theall, Kathy Puyana ;

Jiang, Yuqiu ;

Bartlett, Cynthia Huang ;

Koehler, Maria ;

Slamon, Dennis .

LANCET ONCOLOGY, 2016, 17 (04) :425-439

[6] Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study [J].

Curigliano, G. ;

Gomez Pardo, P. ;

Meric-Bernstam, F. ;

Conte, P. ;

Lolkema, M. P. ;

Beck, J. T. ;

Bardia, A. ;

Martinez Garcia, M. ;

Penault-Llorca, F. ;

Dhuria, S. ;

Tang, Z. ;

Solovieff, N. ;

Miller, M. ;

Di Tomaso, E. ;

Hurvitz, S. A. .

BREAST, 2016, 28 :191-198

[7] Targeted Neoadjuvant Therapies in HR+/HER2-Breast Cancers: Challenges for Improving pCR [J].

Dey, Nandini ;

Aske, Jennifer ;

De, Pradip .

CANCERS, 2021, 13 (03) :1-14

[8]

Fasching PA., 2020, ANN ONCOL, V31, DOI [10.1016/j.annonc.2020.08.377, DOI 10.1016/J.ANNONC.2020.08.377]

[9] Timeline - The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited [J].

Fidler, IJ .

NATURE REVIEWS CANCER, 2003, 3 (06) :453-458

[10] Palbociclib and Letrozole in Advanced Breast Cancer [J].

Finn, Richard S. ;

Martin, Miguel ;

Rugo, Hope S. ;

Jones, Stephen ;

Im, Seock-Ah ;

Gelmon, Karen ;

Harbeck, Nadia ;

Lipatov, Oleg N. ;

Walshe, Janice M. ;

Moulder, Stacy ;

Gauthier, Eric ;

Lu, Dongrui R. ;

Randolph, Sophia ;

Dieras, Veronique ;

Slamon, Dennis J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (20) :1925-1936

← 1 2 3 4 →